From: gts (gts_2000@yahoo.com)
Date: Tue Jan 28 2003 - 20:36:44 MST
Rafal writes:
> ### The data are largely inconclusive, with the studies most
> favorable to selegiline being criticized for methodological failings.
> Coupled with the high cost of Deprenyl, this makes the case for its
> use quite shaky.
There was, for a short time, fear that use of selegiline in combination
with levodopa increased mortality rates in Parkinson's patients. However
subsequent studies proved that fear to be unjustified.
There is a tremendous amount of favorable research into deprenyl for
various purposes. It increases lifespan in mice and dogs (and humans,
hopefully). It's also an excellent antidepressant, especially when taken
with DL-phenylalanine and B-6 (it increases levels of the natural mood
enhancer phenylethylamine, and selectively inhibits the MAO-B enzyme
that breaks down dopamine). It enhances libido. It is neuroprotective;
it almost certainly prevents or delays the onset of parkinson's disease
in addition to being a treatment for it. It helps people to quit
smoking. And it has already been approved as a treatment for cognitive
dysfunction in senile dogs, under the trade name Anipryl. Yes,
selegiline makes old dogs smart enough to learn new tricks...
-gts
This archive was generated by hypermail 2.1.5 : Sun Feb 02 2003 - 21:26:03 MST